Home → Breast cancer → Current issues

Current issues in breast cancer

Current issues highlight some of the latest research into breast cancer, new therapies becoming available and new drug treatments coming to the market.

High dose chemotherapy and Autologous Re-infusion of blood progenitor/stem cells for high risk adjuvant or metastatic patients

For the last few years, what was a well established dictum in breast cancer chemotherapy circles, viz. that there was a dose response relationship for the efficacy of chemotherapy in this disease, has...

Scar-free breast reconstruction technique – a claim that is bound to produce headlines

Dr. Gino Rigotti (head of plastic surgery at Verona General Hospital claimed at the 68th annual meeting of American Society of plastic surgeons that he had devised at technique to achieve this...

Anastrozole as effective as Tamoxifen in metastatic breast cancer?

An American trial (called trial 0030), involving 353 post-menopausal women with breast cancer and treated with either tamoxifen or anastrozole (an inhibitor of the conversion of the bodies own natural...

The discovery of Cytokeratin positive cells in the bone marrow of ostensibly localised breast cancer patients

A recent publication from Germany endorses previous work from the UK that the discovery of cancer cells (even at very low levels) in the bone marrows of patients presenting with localised breast...

Adjuvant Radiotherapy in conserved breasts and patients with small primary breast cancers

A recent analysis of patient data from Boston USA examined the follow up of 81 patients who had undergone breast conserving surgery for good prognosis T1 breast cancers. In the group, the...

Adjuvant Systemic (i.e. Chemo Or Hormonal) therapy for small primary breast cancer patients

A recent sub-group analysis of patients in NSABP (the American: National Surgical Adjuvant Breast Project) trials, and all with primary breast cancers smaller than 1 cm in diameter, has recently been...

Herceptin plus chemotherapy

The addition of Herceptin to standard chemotherapy in patients with HER-2 expressing metastatic breast cancer increases the response rate over the standard chemotherapy alone.

The effect of age on overall prognosis for breast cancer – a population based study + implications for therapy

Although by no means the first study to report on the influence of age at presentation of breast cancer on prognosis, the recent report and editorial in the British Medical Journal on this subject are...

Taxol plus Adriamycin chemotherapy

A multicentre European trial’s findings add to those of accumulating American data that the combination of Taxol and adriamycin (doxorubicin) chemotherapy is superior to standard FAC/FEC...

Capecitabine plus Taxotere in metastatic breast cancer

At the 23rd San Antonio Breast cancer symposium, data were presented that showed that the addition of capecitabine to docetaxel/taxotere (one of the taxane group of cytotoxic chemotherapy agents that...

Jump to: [ 1 2 3 ]